Adherence to and determinants of guideline‐recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice
Sign Up to like & getrecommendations! Published in 2021 at "Cancer"
DOI: 10.1002/cncr.33514
Abstract: Anti human epidermal growth factor receptor 2 (anti‐HER2) therapy with trastuzumab improves overall survival in patients with advanced, HER2‐positive gastroesophageal adenocarcinoma (GEA) and is now incorporated into national guidelines. However, little is known about adherence… read more here.
Keywords: routine practice; gastroesophageal adenocarcinoma; adherence determinants; therapy ... See more keywords